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http://www.biomedcentral.com/1746-6148/8/84RESEARCH ARTICLE Open AccessVaccination prepartum enhances the beneficial
effects of melatonin on the immune response
and reduces platelet responsiveness in sheep
Sergio Regodón1, Asunción Ramos1, María P Míguez2, Antonio Carrillo-Vico3, Juan A Rosado4 and Isaac Jardín4*Abstract
Background: Melatonin regulates several physiological processes and its powerful action as antioxidant has been
widely reported. Melatonin acts modulating the immune system, showing a protective effect on the cardiovascular
system and improving vaccine administration as an adjuvant-like agent. Here, we have investigated the role of
melatonin as an adjuvant of the Clostridium perfringens vaccine in prepartum sheep and whether melatonin
modulates platelet physiology during peripartum.
Results: The experiments were carried out in peripartum sheep from a farm located in an area of
Mediterranean-type ecosystem. Plasma melatonin levels were determined by ELISA and sheep platelet aggregation
was monitored using an aggregometer. Here we demonstrated for the first time that plasma melatonin
concentration were higher in pregnant (125 pg/mL) than in non-pregnant sheep (15 pg/mL; P< 0.05).
Administration of melatonin prepartum did not significantly modify platelet function but significantly improved the
immune response to vaccination against C. perfringens.
Conclusion: Administration of melatonin as an adjuvant provides a significant improvement in the immune
response to vaccine administration prepartum against C. perfringens.
Keywords: Clostridium perfringens, Immune response to vaccination, Melatonine, Platelet aggregation, Pregnant
sheepBackground
Melatonin (N-acetyl-5-methoxy-tryptamine), a hormone
produced in the pineal gland and a number of other cells
and organs, regulates a number of physiological pro-
cesses either by its powerful ability to scavenge reactive
oxygen species, interaction with intracellular molecules
or via activation of the G protein-coupled melatonin
receptors, MT1 and MT2 [1-3]. Melatonin regulates the
immune system by affecting cytokine production, enhan-
cing the production of several T helper cytokines and
modulating the IL-2/IL-2R system [4-6]. Melatonin has
been shown to exert a positive effect as an adjuvant of a
number of vaccines [7-11]. Platelet function is also regu-
lated by melatonin binding to high-affinity sites [12],* Correspondence: ijp@unex.es
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reproduction in any medium, provided the orwhich results in enhanced platelet responsiveness to
physiological agonist and inducing beneficial effects on
platelet function and haemostasis [8].
Enterotoxemia, caused by Clostridium perfringens, is
one of the most frequently occurring diseases in all spe-
cies of domestic animals and humans inducing gastro-
intestinal and enterotoxemic diseases in animals [13-15].
The bacterium is a normal inhabitant of the intestine
where it produces small amounts of toxin that, under
normal conditions, are removed by gut movements or are
inactivated by circulating antibodies. Prepartum vaccin-
ation of sheep has been recommended due to the signifi-
cant increase in lamb antibody concentration compared
to lambs reared by unvaccinated sheep [16]. In addition,
this manoeuvre has been found to reduce the frequency
of fecal shedding of serogroup C1 salmonellae during the
peripartum period [17]. Here we have investigated the
effect of melatonin administration as an adjuvant of
the C. perfringens vaccine administered prepartum onal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Plasma melatonin concentration (pg/mL) at the time of the vaccination procedure at 10:00 A.M
Treatment Day
0 21 42 60 90
I. Control 123± 10 132 ± 12 127± 12 131 ± 8 126 ± 10
II. Melatonin Implant 125± 10 277 ± 14*† 296± 15*† 292 ± 12*† 261 ± 10
III. Vaccine 120± 14 126 ± 10 124± 12 128 ± 12 130 ± 10
IV. Vaccine+Melatonin Implant 126± 12 295 ± 11*† 328± 13*† 313 ± 9*† 287 ± 14*†
Values represent mean melatonin concentration as determined by enzyme-linked immunosorbent assay (ELISA). Data are expressed as pg/mL and presented as
mean ± S.E.M. of 10 experiments. * P< 0.05 compared with day 0. † P< 0.05 compared with their respective control in non-vaccinated animals.
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whether vaccination against C. perfringens alters platelet
function, as shown for the vaccine against Dichelobacter
nodosus [8].
Results and discussion
Rectal temperature, as well as the observation of pos-
sible local or general adverse reactions, is important for
the evaluation of the innocuousness of vaccine or mela-
tonin administration. We have not found any local or
general clinical signs, including granulomas, after ad-
ministration of the vaccine or subcutaneous implants of
melatonin in our experimental groups. In addition, the
rectal temperature was in the physiological range.
Serum concentration of melatonin in the different ex-
perimental groups is shown in Table 1. In control ani-
mals (not vaccinated, not treated with melatonin), the
plasma level of melatonin was quite stable with no sig-
nificant changes during the performance of the experi-
ment. Vaccination per se had no significant effect on the
serum level of melatonin. As expected administration of
melatonin by implant induced a significant increase in
the serum concentration of melatonin, which was main-
tained elevated for 60 days and then returned to basal
levels in animals with melatonin implant.
Melatonin plays a role in synchronizing the reproduct-
ive responses of animals to environmental light condi-
tions; it has been reported that serum melatonin levels
during human pregnancy are higher than in a non-
pregnant state [18]. Here, we showed for the first time
in sheep, the differences in plasma melatonin concentra-
tion between non-pregnant and pregnant sheep. As weTable 2 Serum antibody levels at the different treatments
Treatment
0 21
I. Control 13 ± 2 12 ± 3
II. Melatonin Implant 12 ± 2 16 ± 3
III. Vaccine 16 ± 3 40± 6*†
IV. Vaccine +Melatonin Implant 14 ± 3 52 ± 5*†}†
Values represent mean antibodies levels as determined by microagglutination assay
with day 0. † P< 0.05 compared with their respective control in nonvaccinated anim
compared with vaccinated animals.showed previously, sheep in non-gestational state have an
average plasma melatonin concentration of 15 pg/mL [8],
considerably smaller than pregnant sheep (125 pg/mL)
(Table 1). Differences in plasma melatonin concentration
may be due to strong melatonin antioxidant properties, as
well as, as previously postulated, high levels of melatonin
during pregnancy may be one of the factors that reduce
oxidative damage from ROS in the placenta and systemic
endothelial cells [18-21].
Plasma antibody concentration in the different experi-
mental groups is shown in Table 2. As expected, in con-
trol subjects and those treated by melatonin implants
the plasma antibody concentration was unaltered during
the experiment, while vaccine administration increased
significantly plasma antibody concentration reaching
the highest level after 60 days of vaccination (Table 2;
P< 0.05). As shown in Table 2, in animals treated with
melatonin implants the concentration of plasma anti-
bodies was significantly greater after vaccination, which
further support a positive role of melatonin in antibody
production upon vaccination, as described in non-
pregnant sheep [10]. Interestingly, while the effect of
melatonin on the serum antibody level after vaccination
of non-pregnant sheep was found to be slightly greater
but not statistically different from the levels in vaccinated
animals in the absence of melatonin [10], when the vac-
cination takes place prepartum, the serum antibody con-
centration was significantly greater in vaccinated controls
in the presence of melatonin; thus suggesting that the
time of vaccination plays a important role in the effect of
melatonin on the immune response, being more effective
when administered prepartum.Day
42 60 90
14 ± 3 16± 4 15± 3
14± 4 13± 3 15± 2
90± 5*† 104 ± 4*† 70 ± 5*†
112 ± 6*†}† 141 ± 5*†}† 97 ± 4*†}†
s. Data are presented as mean ± S.E.M. of 10 experiments. * P< 0.05 compared
als. } P< 0.05 compared with the application of melatonin implants. † P< 0.05
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of immune responses besides antibody production, in-
cluding enhance antigen presentation to the immuno-
competent cells, as described in mice, where melatonin
improved antigen presentation by macrophages, by in-
creasing the expression of MHC class II and stimulated
activation of T helper cells [22,23]. Furthermore, mela-
tonin may modulate the production of cytokines such as
IL-2, INF-γ and IL-6 and increasing production IL-12 by
monocytes as demonstrated in cultured human mono-
nuclear cells [24], thus promoting Th1 cell response. In
addition, melatonin may also bind to high affinity recep-
tors present on Th2 lymphocytes from human bone
marrow thus increasing the levels of IL-4 [25], increasing
the production of IL-10 and decreasing of TFN-α in
mice sensitized with ovalbumin injected with complete
Freund’s adjuvant, activating the Th2 response [26].Figure 1 Effect of melatonin administration on the percentage of thro
non-vaccinated sheep. Platelets from sheep vaccinated or not against Clo
as indicated, were stimulated in a medium containing 1 mM Ca2+ with 1 U
experiments. *P< 0.05 compared with their respective controls.We have further investigated whether vaccination
against C. Perfringens (D serotype) in the absence or pres-
ence of melatonin might have any effect on platelet func-
tion, and thus, hemostasis. Hence, we tested ex vivo
platelet aggregation in response to the physiological agon-
ist thrombin in the four experimental groups. The per-
centage of aggregation upon stimulation with 0.5 U/mL
thrombin decreased significantly after partum in all the
experimental conditions (Figure 1; P< 0.05; n = 10–12).
Similar results were obtained when we calculated the
rate of aggregation (Figure 2; P< 0.05; n = 10–12).
Interestingly, the lag-time in response to thrombin was
not altered in any of the groups investigated (Figure 3).
Vaccination or treatment with melatonin did not
modify agonist-induced aggregation in sheep during the
last stages of pregnancy and postpartum period. We
have found that in pregnant sheep serum melatoninmbin-induced platelet aggregation in vaccinated and
stridium perfringens type D and treated with melatonin or the vehicle,
/mL thrombin. Data are mean± S.E.M. of 10–12 independent
Figure 2 Effect of melatonin administration in the rate of thrombin-induced platelet aggregation in vaccinated and non-vaccinated
sheep. Platelets from sheep vaccinated or not against Clostridium perfringens type D and treated with melatonin or the vehicle, as indicated, were
stimulated in a medium containing 1 mm Ca2+ with 1 U/mL thrombin. Data are mean± S.E.M. of 10–12 independent experiments. *P< 0.05
compared with their respective controls.
Figure 3 Effect of melatonin administration in the lag-time of thrombin-induced platelet aggregation in vaccinated and non-
vaccinated sheep. Platelets from sheep vaccinated or not against Clostridium perfringens type D and treated with melatonin or the vehicle, as
indicated, were stimulated in a medium containing 1 mm Ca2+ with 1 U/mL thrombin. Data are mean±S.E.M. of 10–12 independent experiments.
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pregnant subjects [8]. Therefore, melatonin administra-
tion results in a 2- over 20-fold increase in melatonin
concentration in pregnant and non-pregnant animals,
respectively, where the serum melatonin concentration
reached similar values after exogenous administration.Conclusions
We have found that pregnant sheep serum melatonin
concentration is elevated as compared to non-pregnant
animals. The enhanced level of melatonin in pregnant
subjects may be attributed to a physiological effect to
avoid oxidative disorders derived from pregnancy,
where melatonin could exert an important role as anti-
oxidant preventing platelet hyperactivation, due to its
inhibitory effect over COX-1 and arachidonic acid-
induced aggregation. The lack of effect of melatonin on
platelet aggregation might be explained by desensitization
of melatonin receptors after prolonged exposure to ele-
vated concentrations of melatonin, as previously reported
[27].
The ability of adjuvants to enhance the immune
responses to vaccine antigen has long been investigated
and the search for adequate adjuvants is critical for im-
proving the performance of existing vaccines, and a role
of melatonin as adjuvant has been described [7-11]. Our
results indicate that melatonin significantly enhanced
the immune response to vaccination against the Clos-
tridium perfringens type D, which, together with our pre-
vious studies in non-pregnant sheep, strongly suggest
that melatonin enhances the immune response to vac-
cination. In addition to our previous findings, here we
demonstrate for the first time the beneficial effects of
melatonin on the immune response to vaccination when
administered prepartum.Table 3 Group composition and chronological schedule of tas
Group Composition
I Mock control
II Control+Melatonin implant
III Vaccine
IV Vaccine+Melatonin implant
Day 0 21
Vaccination + +
Melatonin implant + +
Blood collection + +
Platelet function + +
Melatonin measurement + +
Rectal temperature + +
Local reaction + +
General reaction + +Methods
Materials
Apyrase (grade VII), EGTA, aspirin, bovine serum albu-
min (BSA), melatonin and thrombin were from Sigma–
Aldrich 1(Madrid, Spain). Calcein and fura-2/AM were
from Molecular Probes (Leiden, The Netherlands). Mela-
tonin ELISA was from IBL (Hamburg, Germany). All
other reagents were purchased from Panreac (Barcelona,
Spain).
Experimental set-up and animal immunizations
The experiments were carried out in a commercial farm
located in an area of Mediterranean type ecosystem in
Cáceres (Spain) over a 8-months period (October to May,
2009–2010). A total of 40 pregnant sheep (30 months old;
average weight 47.64 Kg) of the Merino breed and meat
producing were used. Animals were kept without restraint
in their habitual herd and were grown up in an extensive
breeding system accordingly with regional and European
Union standard regulations.
The study was approved by the Ethical Committee of
the University of Extremadura (Cáceres, Spain) in ac-
cordance with the National Institute of Health Guide for
the Care and Use of Laboratory Animals.
The animals were divided into four different experi-
mental groups; each one comprised of 10 female sheep.
Formulation of the immune-preparations, dosage, ad-
ministration routes as well as different tests carried out
for each animal are summarized (Table 3). Animals were
treated 10 days before the onset of the experiment with
Ivermectine subcutaneously a dose of 1 ml per animal
(IvomecTM, Merial Laboratories S.A., Barcelona, Spain)
to deworm them. Eight days later first blood samples
from the 40 animals were drawn to check blood levels of
melatonin and platelet function. Blood samples and sera
preparation were performed according to standardks carried out in each animal
Dose Administration
2 mL subcutaneus
2 mL subcutaneus
42 60 90
+ + +
+ + +
+ + +
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(10.00 A.M.).
Sheep were subjected, on deworming day, to estrus
synchronization protocol, involving intravaginal sponge
implantation containing flugestone acetate (Chronogest
20 mg, Intervet Laboratories, Madrid, Spain). 14 days
after synchronization, we inoculated 50 UI of PMSG
(Foligon, Intervet Laboratories, Madrid, Spain) via intra-
muscular injection to each subjects. Natural mating took
place 55 hours after application of PMSG and all the 40
sheep became pregnant. Animal gestation state was cor-
roborated by performing trans-abdominal ultrasound
using a 5 MHz linear probe (HS-1500 V, Honda Elec-
tronics Co., LTD., Japan). Day 130 of gestation was con-
sidered as the day 0 (D 0) of the study. Vaccination of
the 20 female sheep, corresponding to groups III and IV
(Table 3), was performed subcutaneously in the area of
the axilla with a dose of 2 mL of the vaccine. The
immune-preparation consisted of C. Perfringens type D
(Ovejero Laboratories, Leon, Spain). Administration of
the booster vaccine injection was carried out at D. 21.
To assess the overall response to the vaccination proced-
ure, some basic clinical signals were monitored (Table 3).
Rectal temperature was recorded during 3 consecutive
days after first vaccination and re-vaccination. Rectal
temperature was always monitored at the same time
(10.00 A.M.), to avoid fluctuations due to defferent
metabolic conditions. We also assessed the general and
local adverse reactions by clinical and macroscopic ob-
servation, to detect any reaction due to the vaccination.
The clinical observation of the animals the day of first
and booster vaccination and three days after vaccination
did not show granulomas or other relevant signs at the
administration sites. The rectal temperature of the ani-
mals included in the experiments was homogeneous and
clinically normal after the administration of the vaccine
or melatonin, ranging from 38.7 to 39.5 °C.
Melatonin treatment
On day 0 and 21, female sheep from groups II and IV
received slow release 36 mg/animal subcutaneous
implants of melatonin in the left ear (MelovineW, Ceva
Sante Animale, France).
Platelet preparation
Blood was obtained from sheep, and mixed with one-
sixth volume of acid/citrate dextrose anticoagulant con-
taining (in mm): 85 sodium citrate, 78 citric acid and
111 D-glucose [28,29]. Platelet-rich plasma was then
prepared by centrifugation for 5 min at 700 g and aspirin
(100 μm) and apyrase (40 μg/mL) were added. Cells were
collected by centrifugation at 350 g for 20 min and
resuspended in HEPES-buffered saline (HBS) containing
(in mm): 145 NaCl, 10 HEPES, 10 D-glucose, 5 KCl, 1MgSO4, pH 7.45 and supplemented with 0.1%w/v BSA
and 40 μg/mL apyrase.
Cell viability
Cell viability was assessed using calcein and trypan blue.
For calcein loading, cells were incubated for 30 min with
5 lm calcein-AM at 37 °C, centrifuged and the pellet was
resuspended in fresh HBS. Cells were treated with the
different inhibitors, centrifuged and resuspended in
HBS. Fluorescence was recorded from 2 mL aliquots
using a spectrophotometer (Varian Ltd, Madrid, Spain).
Samples were excited at 494 nm and the resulting fluor-
escence was measured at 535 nm. The results obtained
with calcein were confirmed using the trypan blue exclu-
sion technique. About 95% of cells were viable in our
platelet suspensions and no effect was observed after
sheep treatment with melatonin.
Platelet aggregation
The percentage, rate and lag-time of aggregation in
washed platelets were monitored using a Chronolog
aggregometer (Havertown, PA, USA) at 37 °C under stir-
ring at 1200 rpm [30]. The percentage of aggregation or
amplitude is estimated as the percentage of the differ-
ence in light transmission between the platelet suspen-
sion in HBS and HBS alone and indicates the percentage
of platelets that aggregate in response to an agonist.
Resting platelets in suspension are arbitrarily considered
by the aggregometer as 0% aggregation and HBS is con-
sidered to be 100% aggregation. The rate, or slope, of
the aggregation is the percentage change of aggregation
per minute. The lag-time is the time between platelet
stimulation and the initiation of aggregation. Percentage
of aggregation, aggregation rate and lag-time were calcu-
lated using AGGRO/LINKW. As previously reported
[28], treatment of platelets, suspended in a medium con-
taining 1 mM Ca2+, with 1 U/mL thrombin induced
rapid aggregation characterized by a large increase in
light transmission as the platelets aggregated (Figure 1A;
n = 10).
Measurement of melatonin in serum
Blood samples (10 mL/animal) were collected at the
same time (10.00 a.m.) by syringe and transferred to a
tube containing serum-separating gel. Samples were cen-
trifuged at room temperature for 15 min at 300 g. Serum
was then divided into aliquots in Eppendorf vials and
kept frozen at −30 °C until the time of assay.
Melatonin levels were determined by a Melatonin
ELISA (Immuno Biological Laboratories, Hamburg, Ger-
many) according to the manufacturer’s instructions.
Melatonin from 0,5 mL of the samples, standards and
controls was extracted (90–100% yield recovery) using
C18 reversed phase columns (Immuno Biological
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(after evaporating methanol) were stored at −20 °C for
up to 48 h. Melatonin levels were measured in duplicate
using 96-well microtiter plates coated with captured
antibody goat anti-rabbit Ig. Each microtiter plate was
filled either with 50 mL blank reagent, extracted calibra-
tors, extracted samples or extracted standard solutions
(containing 0, 3, 10, 30, 100, or 300 pg/ml of melatonin).
Then, 50 mL of melatonin biotin and 50 mL of rabbit-
antiserum were added into each well, shaken carefully,
sealed with adhesive foil and incubated overnight (14–
20 h) at 2–8 °C. After washing three times with 0,25 mL
diluted assay buffer, 0,15 mL of anti-biotin conjugate to
alkaline phosphatase was added to each well and incu-
bated for 2 h at room temperature. The reaction was
developed using p-nitrophenyl phosphate and optical
densities were determined at 450 nm in an automatic
microplate reader.
The sensitivity of the MLT assay was 3 pg/mL. Both the
intra and inter-assay coefficients of variation (CV) were
<10%. For simplicity, the results are expressed as the re-
spective means in pg/mL of the serum melatonin levels.
Measurement the titer of antibodies in serum
The titer of antibodies was determined by microaggluti-
nation assays. Briefly, serial dilutions of the sera up to 1/
10240 in phosphate buffer saline O (PBS-SO) were ap-
plied using 96 V bottom plates (Soria Greiner, Spain).
Then, 50 μL of antigen suspensions were deposited in
each well. The plates were incubated at 37 °C for 12 h
and then refrigerated at 4 °C for 2 h before we proceeded
to read them. The appearance of a button at the bottom
of the bowls, due to precipitation of free antigen was con-
sidered a negative result. If, on the contrary, a coloured
diffusion of the contents appears at the bottom of the
bowl, it means agglutination occurred (antigen-antibody
complex) and the result was considered positive.
Statistical analysis
Analysis of statistical significance was performed
using Student’s t-test, Two-way Anova and Bonferroni
posttests. P< 0.05 was considered to be significant.
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